The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB). The Committee first heard from the Minister of Health, the Honourable Jean-Yves Duclos. The Minister’s appearance was followed by witnesses from the Department of Health and the Department of Justice, as well as Mélanie Bourassa Forcier, Professor at the University of Sherbrooke and the former Acting Chair of the PMPRB.
The Committee will reconvene on May 2, 2023, to hear from Matthew Herder, Associate Professor at Dalhousie University and former board member of the PMPRB, as well as the current Executive Director of the PMPRB, Douglas Clark.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency announces consultation on streamlined review process and new reconsideration/resubmission procedures
On January 29, 2026, Canada’s Drug Agency (CDA) published Improvements to the Drug Reimbursement Review Process, which includes a section for consultation on proposed changes to the reimbursement re...Read More -
PMPRB consults on proposed Practice Directions for PMPRB hearings
The Patented Medicine Prices Review Board (PMPRB) holds public hearings in two types of matters: to determine whether the price of a medicine is excessive; and to determine whether a rights holder ha...Read More -
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More
